Fib 4 Calculator - Age-Aware Liver Fibrosis Index

A fib 4 calculator is a non-invasive screening tool for liver fibrosis that combines a patient's age, AST, ALT, and platelet count into a single index, then reads that index against published cutoffs to estimate the chance of advanced fibrosis without a liver biopsy.

• • NAFLD and NASH triage: Adults with suspected non-alcoholic fatty liver disease who need a low-cost first-line screen before elastography.
• • Hepatitis C follow-up: Specialists tracking chronic hepatitis C patients between visits.
• • Hepatitis B monitoring: Adults with chronic hepatitis B who already have routine AST, ALT, and complete blood count panels.
• • Resource-limited clinics: Practices without FibroScan or on-site hepatology who need a structured numeric baseline from routine labs.

FIB-4 is a screening score, not a diagnosis. Sterling et al. first published the formula in 2006 in an HIV/HCV cohort, and Shah et al. validated the standard NAFLD cutoffs of 1.30 and 2.67 in 2009. The McPherson 2017 cutoff of 2.0 for adults aged 65 and over corrects a known specificity drop in older adults.

When the team wants a second non-invasive fibrosis screen that uses the same AST and platelet inputs, APRI Calculator returns the AST to Platelet Ratio Index with the WHO 2015 cutoffs at 0.5, 1.5, and 2.0.

The fib 4 calculator takes four routine numbers, applies the Sterling square-root formula, rounds the result to two decimal places, and reads it against the Shah 2009 NAFLD 1.30 and 2.67 cutoffs, or 2.0 and 2.67 in age-adjusted mode.

• Age: Whole-year age at the time of the lab draw. Age multiplies the numerator.
• AST: Aspartate aminotransferase in U/L. AST is in the numerator, so a higher AST lifts the index.
• ALT: Alanine aminotransferase in U/L. ALT is square-rooted in the denominator, so a low ALT inflates the index.
• Platelet count: Platelet count in 10^9 per L. Lower counts, a sign of portal hypertension, push the index up.

The calculator rounds to two decimal places so the result matches the precision used in the published validation studies. The AST/ALT ratio is shown next to the index because it is a quick companion marker from the same labs.

According to Sterling et al. (Hepatology 2006), FIB-4 is age in years times AST in U/L, divided by platelet count in 10^9 per L times the square root of ALT in U/L, with original HIV/HCV cutoffs of 1.45 and 3.25. The 1.30 and 2.67 NAFLD cutoffs used here come from Shah et al. (Clin Gastroenterol Hepatol 2009), which validated FIB-4 against biopsy in 541 NAFLD adults.

Because the fib 4 calculator also returns the De Ritis ratio, AST/ALT Ratio Calculator is the natural next step when the user wants the same numerator-over-denominator logic broken out as a standalone marker.

Four routine labs drive the score, and each one moves it in a different direction.

Reading the four levers together is more useful than reading the index in isolation. A 60-year-old with normal AST and ALT but a platelet count near 90 x 10^9 per L will still score high, pointing back to portal hypertension. Per McPherson et al. (Am J Gastroenterol 2017), raising the lower cutoff to 2.0 in patients aged 65 and over keeps specificity around 70 percent, which the 1.30 cutoff cannot do in that age band.

When a patient with chronic liver disease also needs a parallel kidney function screen before any contrast imaging or diuretic change, GFR Calculator turns serum creatinine, age, and sex into an eGFR using CKD-EPI.

Treat the form as a checklist that mirrors the labs already on file. Work through the four numbers, pick the cutoff mode, and read the interpretation band with the rest of the clinical picture.

1. 1 Enter the patient age: Type the patient's age in whole years at the time of the lab draw. The number multiplies the numerator.
2. 2 Enter AST, ALT, and the platelet count: Pull AST and ALT from the most recent liver function panel and the platelet count from the complete blood count. Use AST and ALT in U/L and platelets in 10^9 per L.
3. 3 Pick the cutoff mode: Keep auto mode to apply the McPherson 2017 age-adjusted lower cutoff of 2.0 for patients aged 65 and over, or switch to standard mode to apply the Shah 2009 NAFLD 1.30 and 2.67 cutoffs to every adult.
4. 4 Read the index and the band: Read the rounded FIB-4 index, the AST/ALT ratio, and the fibrosis band. Below the lower cutoff is low risk, above 2.67 is high risk, and anything in between is indeterminate.
5. 5 Pair the result with the clinical context: Document the score, the cutoff mode, and the lab date in the chart note, then review the result alongside imaging, viral load, and elastography before changing any treatment plan.

A 55-year-old with chronic hepatitis B has AST 40 U/L, ALT 35 U/L, and platelets 200 x 10^9 per L. The index is 1.86, in the indeterminate band. The next step is elastography or specialist referral, not an immediate treatment change.

When the platelet count driving the fib 4 result is also being reviewed for a possible heparin reaction in a hospitalised patient, 4TS Score tallies the four T categories into a HIT pretest probability band.

A FIB-4 score can be worked out on paper, but a calculator makes the arithmetic consistent, traceable, and easy to revisit.

• • Built on routine labs: The four inputs are already on most adult liver and complete blood count panels.
• • Shah 2009 NAFLD cutoffs built in: The 1.30 and 2.67 cutoffs are applied automatically, which keeps the interpretation consistent with the NAFLD triage cutoffs validated in 541 biopsy-confirmed adults.
• • Age-adjusted mode for adults aged 65 and over: The McPherson 2017 lower cutoff of 2.0 is one click away, which protects specificity in older adults where the 1.30 cutoff produces too many false positives.
• • Companion AST/ALT ratio: The De Ritis ratio is shown next to the index, giving a second liver marker without re-entering data.
• • Quick to re-run: Each change updates the index instantly, which makes it practical after every new lab draw.
• • Useful in resource-limited clinics: FIB-4 is recommended in AASLD and IDSA hepatitis C guidance as a low-cost first-line screen for settings where elastography is not readily available.

The score is a planning tool, not a treatment recommendation. The AASLD and IDSA hepatitis C guidance is explicit that FIB-4 is for screening and triage, with elastography or biopsy remaining the next step when the result will change care.

When the clinic wants a second point-based clinical score to compare workflows against, TI-RADS Calculator totals ACR ultrasound feature points against biopsy and follow-up size thresholds.

Several clinical and lab factors can move the index up or down, and some have nothing to do with fibrosis.

• • FIB-4 is a screen, not a stand-alone diagnosis. A score in the indeterminate or high-risk band still needs elastography or liver biopsy confirmation before any treatment escalation.
• • The score is least accurate in the indeterminate zone between 1.30 and 2.67. Patients in that band often need elastography, FibroScan, or a second non-invasive marker such as APRI to clarify the fibrosis stage.
• • Inputs come from a liver function panel, a complete blood count, and a date of birth, so confirm AST, ALT, and platelet count are from the same draw before acting on the score.

Bleeding risk, kidney function, pregnancy status, and the treatment plan matter for what to do with the result, but those are not part of the score. The fib 4 calculator intentionally stops before the next clinical step so the result is a screen, not a treatment order.

Per AASLD and IDSA HCV Guidance on hcvguidelines.org, non-invasive serum markers such as FIB-4 and APRI are recommended for the initial assessment of liver fibrosis in chronic hepatitis C, with elastography reserved for indeterminate or high-risk results.